UNSPSC 51172163: Bietamiverine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C19H30N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 646WTQ0G3E, chemically known as 1-piperidineacetic acid, alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride but more generally known as bietamiverine hydrochloride, which bears US NIH Compound Identifier 72063. Most nations, for tariff and trade purposes, schedule bietamiverine hydrochloride under HS 29333999.

As of Q4 2014, BIETAMIVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Bietamiverine hydrochloride bears US NLM NCI C73602. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)N2CCCCC2.CL.

UNSPSC 51172163 Bietamiverine hydrochloride is a Commodity code that maps to pharmaceutical procurement activity, though recent state and local opportunities tagged under this code show limited direct demand for the named active pharmaceutical ingredient. Instead, the code appears in contexts where state and local buyers are procuring broader drug testing services, pharmaceutical distribution infrastructure, and generic multi-source pharmaceutical supply. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, requesting offender specimen collection and drug testing services—which includes immunoassay screening and confirmatory testing via LC/MS/MS or GC/MS—due July 23, 2026, with an estimated contract value of $600,000 over two years plus optional renewals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, due March 26, 2026, requiring vendors to supply through three authorized wholesalers and certify compliance with cGMP and DSCSA standards. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment capabilities, signaling exploratory procurement strategy rather than immediate contract award.

Activity under this code spans state pharmacy benefit administration, county corrections and public safety, and multi-state cooperative purchasing vehicles serving school districts and local government entities. Texas, Minnesota, and Oregon show recent activity. The Collin County RFP (scoring vendor understanding 30 points, firm qualifications 25 points, client references 15 points, and cost 30 points, with optional Phase 2 demonstrations worth up to 30 points) awards to the responsible contractor representing the best evaluated offer; the contract commences September 1, 2026, with an anticipated award date of August 10, 2026. The MMCAP RFP (75 percent weight on price competitiveness, 10 percent on fixed pricing, 5 percent each on compliance, EDI capability, and administrative fee agreement) made awards effective July 1, 2026. The Texas HHS RFI is exploratory and carries no award value or committed timeline; responses inform future formal procurement strategy.